Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 19/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9211036 | 0.90 | CYSLTR1 (0.52) | ALOX5AP | |
| SCHEMBL16046913 | 0.84 | ALOX5AP (0.60) | ALOX5AP | |
| SCHEMBL9530848 | 0.80 | CYSLTR1 (0.59) | — | |
| SCHEMBL9199458 | 0.80 | GPBAR1 (0.59) | — | |
| SCHEMBL9529563 | 0.79 | CYSLTR1 (0.63) | ALOX5AP | |
| SCHEMBL9208722 | 0.79 | CYSLTR1 (0.60) | — | |
| SCHEMBL9529814 | 0.79 | CYSLTR1 (0.52) | — | |
| SCHEMBL9212939 | 0.78 | PTGS1 (0.61) | ALOX5AP | |
| SCHEMBL9504272 | 0.77 | ALOX5AP (0.60) | ALOX5AP | |
| SCHEMBL9530803 | 0.76 | PDE10A (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1579010-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION; METHODS OF TREATMENT | Decode Genetics EHF. (IS) | 2005-09-28 | — | — | EP | claimed |
| WO-2004035741-A2 | SUSCEPTIBILITY GENE FOR MYOCARDIAL INFARCTION; METHODS OF TREATMENT | DECODE GENETICS EHF. (IS) | 2004-04-29 | — | — | WO | claimed |
| US-20120208709-A1 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE | DECODE GENETICS EHF. (IS) | 2012-08-16 | — | — | US | disclosed |
| US-8158362-B2 | Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype | DECODE GENETICS EHF. (IS) | 2012-04-17 | — | — | US | disclosed |
| US-7851486-B2 | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment | DECODE GENETICS EHF. (IS) | 2010-12-14 | — | — | US | disclosed |
| US-20100120045-A1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | DECODE GENETICS EHF (IS) | 2010-05-13 | — | — | US | disclosed |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | DECODE GENETICS EHF. (IS) | 2005-05-26 | — | — | US | disclosed |
| US-6617345-B1 | Cyclooxygenase-2 inhibitor is (5-bromo-2-(4-fluorophenyl )-3-(4-(methylsulfonyl)phey)-thiophene), N-(2-(cyclohexyloxy 4-nitrophenyl)-methanesulfonamide), meloxicam, flosulide or cyclic substituted phenyl sulfones or sulfonamides | G.D. SEARLE & CO. | 2003-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120045-A1 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION | TNNI3, TSG101, ALDH1B1 | ALOX5AP 580/4885 |
| US-20050113408-A1 | peripheral arterial occlusive disease (PAOD); prophylaxis of myocardial infarction by administering an agent that inhibits leukotriene synthesis in vivo for example (R)-(+)-alpha-cyclopentyl-4-(2-quinolinylmethoxy)-Benzeneacetic acid, BAY-X-1005 | ALOX5, ALOX15, ALOX12 | ALOX5AP 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.